drugset
drugset / Trial / NCT03219307

NOVOCART 3D Treatment Following Microfracture Failure

NCT03219307 ↗

Phase 3 Active not recruiting 30 enrolled Aesculap Biologics, LLC
NaSingle-groupOpen-labelTreatment

Summary

This study is prospective single arm extension study of protocol AAG-G-H-1220. It is open only to participants of AAG-G-H-1220 randomized to the Microfracture treatment group.

Timeline

Start
2018-11-30
Primary completion
2026-01
Completion
2029-01

Drugs

EvaluationDrugModalityDoseRoute
Subject NOVOCART 3D Cell therapy — —

Indications

articular cartilage disorder